查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198722

靜脈曲張治療市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Varicose Veins Treatment Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，靜脈曲張治療市場預計將以 6.0% 的複合年增長率增長。

COVID-19 的爆發預計將對市場產生重大影響，因為醫護人員的工作重心已轉移到治療 COVID-19 感染者上。 因此，非緊急情況的治療已成為次要事項。 根據一項名為“COVID-19 時代靜脈實踐的變化”的研究。 根據 2021 年 5 月發表在 Annals of Vascular Surgery 上的“Never Let a Good Crisis Go to Waste”，在 COVID-19 封鎖期間，國民健康保險和私立醫院因靜脈曲張及其並發症而停止治療。 麻醉師會議的短缺導致靜脈曲張手術的數量顯著減少，麻醉師全神貫注於緊急情況，包括 COVID 和非 COVID。 一般來說，老年人口和有合併症的人更容易患上靜脈疾病，如靜脈曲張。 這些人感染 SARS-CoV-2 病毒的風險也增加。 因此，大多數與靜脈曲張治療相關的干預措施在大流行期間被保留和推遲，預計這將對研究市場增長產生重大影響。

靜脈曲張治療市場主要是由於普通人群越來越喜歡這種微創手術、老年人口不斷增加以及用於這種治療的設備技術進步。受以下因素驅動：

此外，靜脈疣患病率上升預計將推動市場增長。 2020 年 2 月發表在 BMC Nursing 上的一篇研究論文“Dhulikhel 醫院護士的靜脈曲張及其危險因素：一項橫斷面研究”表明，靜脈曲張被認為是最常見的慢性靜脈疾病之一。估計全世界有 20-60% 的成年人受到影響。 此外，根據 2020 年 5 月在沙特阿拉伯艾卜哈的《家庭醫學和初級保健雜誌》上發表的題為“沙特阿拉伯艾卜哈教師靜脈曲張的患病率和意識”的研究，近 42% 的教師參加了該研究被診斷為靜脈曲張。 肥胖、長時間站立工作和吸煙，尤其是女性，已被確定為與靜脈曲張發展相關的一些重要風險因素。 此外，由於懷孕期間妊娠子宮增大，已觀察到高血壓和下肢靜脈腫脹以及激素分泌增加削弱靜脈壁，導致靜脈曲張的診斷。

靜脈曲張在老年人群中最常見，隨著老年人口的增加，預計將進一步推動市場。 根據世界衛生組織 2021 年的數據，2015 年至 2050 年間，世界 60 歲及以上人口的比例將從 12% 增加近一倍至 22%。 到 2050 年，全球 80% 的老年人將生活在低收入和中等收入國家。 衰老的速度比過去快了很多。

此外，預計主要市場參與者會增加產品公告，從而推動市場增長。 例如，2020年10月，專注於迴聲療法（使用高強度聚焦超聲或HIFU）的創新公司THERACLION推出了第二代SONOVEIN，這是針對靜脈曲張的HIFU治療方案，獲得了CE標誌。

由於技術的進步和醫療保健系統的改進，預計該市場在預測期內將穩步增長。 然而，與靜脈手術相關的高成本和風險預計會阻礙市場。

靜脈曲張治療市場趨勢

預計激光燒蝕設備在預測期內將大幅增長

激光消融治療為接受靜脈曲張治療的患者提供了顯著的好處，因為它不涉及長期住院或恢復過程中的不適。 借助新技術和研究市場主要參與者研究活動的進步，越來越多地採用激光治療靜脈曲張。

激光消融技術使醫生能夠閉合細小的靜脈曲張和蜘蛛狀靜脈。 這種治療涉及向靜脈發射強烈的光，使受影響的靜脈消失或褪色。 由於醫療成本上升和非侵入性手術的增長趨勢，發達國家對激光療法的使用正在增加。 2022 年 5 月發表在英國外科雜誌上的一項題為“淺靜脈功能不全治療後的壓縮：系統評價”的研究發現，激光消融具有成本效益，並且與隱靜脈反流有關。它被認為是首選的初始治療治療直徑 >3 毫米的有症狀靜脈曲張。 此外，本地靜脈曲張激光器製造商之間的競爭非常激烈。 隨著激光的未來發展和激光治療的簡便性，預計該細分市場將在未來增長。

此外，預計主要市場參與者增加產品發布將在預測期內推動該細分市場的增長。 例如，2022 年 4 月，專注於開髮用於治療血管疾病的準分子激光系統的醫療設備公司 Ra Medical Systems, Inc. 宣布，美國專利商標局已授予該公司一種液體填充激光器，該激光器具有擴展的遠端光學窗口。據報導，它已獲得激光燒蝕專利。

因此，由於上述因素，預計激光燒蝕設備市場在預測期內將實現健康增長。

預計在預測期內北美將主導市場

北美所佔份額最大，預計這一趨勢在預測期內將持續下去。 促進北美靜脈曲張治療市場增長的主要因素包括美國等國家/地區發達的醫療保健系統以及能夠增加市場產品可用性的主要參與者的存在。提到。 此外，由於有利的報銷方案，美國人可以以負擔得起的費用獲得這種治療。

根據 2021 年 12 月在《臨床流行病學和全球健康》雜誌上發表的一項題為“城市警察靜脈曲張風險評估——一項橫斷面研究”的研究，靜脈曲張影響了美國大約 23% 的成年人。影響。 考慮到蜘蛛狀毛細血管擴張和網狀靜脈，其患病率在男性中上升至 80%，在女性中上升至 85%。 原來美國是22分之一。 因此，預計在預測期內，美國人口中靜脈曲張負擔的增加將推動北美地區的研究市場。

然而，儘管主要市場參與者為市場擴張而採取的各種策略（例如產品發布、併購和合作）有望提振區域市場。 例如，2021 年 4 月，Medtronic 啟動了一項調查設備豁免 (IDE) 試驗，以了解用於治療深靜脈疾病的 Abre Vein 自擴張支架系統是否有效和安全。 此外，2021 年 12 月，一家專注於靜脈反流病創新治療程序的私人控股矽谷醫療器械公司 Venclose Inc. 宣布推出一種針對不完全穿通靜脈 (IPV) 的新型微創治療方法。我們已獲得 FDA 批准射頻消融 (RFA) 導管 Venclose Maven 的 510(k) 許可。

因此，由於上述因素，靜脈曲張治療市場有望在預測期內實現健康增長。

靜脈曲張治療市場競爭者分析

靜脈曲張治療市場競爭適中，主要由本地公司組成。 儘管有少數國際公司，但來自不同地區的本地公司主導了整個市場。 隨著醫療器械市場的不斷增長，預計在預測期內將有更多公司研究和滲透市場並佔據相當大的份額。 市場上的主要參與者包括 Medtronic plc、AngioDynamics Inc.、Teleflex incorporated、Lumenis、Quanta System、Biolitec AG、Syneron Medical Ltd 和 Vascular Solutions Inc。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 越來越喜歡微創手術
    • 設備的技術進步
    • 不斷增長的老年人口
  • 市場製約因素
    • 手術費用高
    • 與靜脈手術相關的風險
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按治療類型
    • 靜脈消融
    • 注射硬化療法
    • 手術結紮/解剖
  • 按產品分類
    • 消融設備
      • 射頻消融設備
      • 激光燒灼裝置
    • 靜脈閉合
    • 外科產品
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Candela Medical（Syneron Medical Ltd）
    • Medtronic PLC
    • Boston Scientific（Lumenis Corporation）
    • El. En SpA Group（Quanta System）
    • Teleflex Incorporated
    • Eufoton SRL
    • Biolitec AG（BioMed Technology Holdings Ltd）
    • AngioDynamics Inc.
    • Alma Lasers Ltd
    • Sciton Inc.
    • Won Tech Co. Ltd
    • Dornier MedTech GmbH

第七章市場機會與未來趨勢

簡介目錄
Product Code: 67124

The varicose veins treatment market is expected to register a CAGR of 6.0% over the forecast period, 2022-2027.

The outbreak of COVID-19 is expected to impact the market significantly, as the focus of healthcare professionals has been shifted toward the treatment of COVID-19-infected patients. Thus, the treatment of non-emergency medical conditions was given lesser priority. According to the study titled "Changing Venous Practice in the COVID-19 Era: "Never Let a Good Crisis Go to Waste" published in the Annals of Vascular Surgery in May 2021, The national health services hospital and private hospitals stopped treating people with varicose veins and their complications during the COVID-19 Lockdown. Due to a lack of anesthetic sessions, the number of varicose vein surgeries has decreased significantly, with anesthetists being preoccupied with emergency cases, both COVID and non-COVID. Also, the geriatric population and people with co-morbid conditions are generally prone to develop venous diseases, such as varicose veins. This population is also at higher risk of being infected by the SARS-CoV-2 virus. Hence, most of the interventions related to the treatment of varicose veins are reserved and deferred during the pandemic, which is expected to significantly impact the growth of the studied market.

The market for the treatment of varicose veins is majorly driven by factors such as the growing preference of the general population for minimally-invasive surgeries, the rising geriatric population, and the technological advancements in the devices used for this treatment.

Furthermore, rising prevalence of the vericose vein anticipated to drive the growth of the market. According to a research article titled "Varicose veins and its risk factors among nurses at Dhulikhel hospital: a cross sectional study" published in BMC Nursing in February 2020, varicose veins are considered one of the most common chronic venous disorders, affecting 20-60% of all adults globally. Additionally, according to the study titled "Prevalence and awareness of varicose veins among teachers in Abha, Saudi Arabia" published in the Journal of Family Medicine and Primary Care May 2020 nearly 42% of the teachers who participated in a research study were diagnosed with varicose veins in Abha, Saudi Arabia. Obesity, particularly among women, prolonged standing hours at work, and smoking, are some of the significant risk factors associated with the development of varicose veins. Additionally, varicose veins are observed to be diagnosed during pregnancies due to the enlargement of the gravid uterus, which results in hypertension and distension in the lower-extremity veins and an increase in hormone secretion, leading to the weakening of the venous walls.

Vericose vein is most prevalent in the geriatric population, moreover rising in geriatric population anticipated to boost the market. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. By 2050, 80% of the world's elderly will live in low- and middle-income countries. The population is aging at a much faster rate than in the past.

Additionaly, growing product launches by the key market players anticipated to boost the market growth. For Instance in October 2020, THERACLION an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU), has obtained CE Mark for the second generation of SONOVEIN, it's HIFU treatment solution for varicose veins.

With technological advancements and the growing focus on improvising the healthcare system, the market is expected to witness steady growth over the forecast period. However, the high costs and risks associated with the procedures involved in vein surgeries are expected to hinder the market.

Varicose Veins Treatment Market Trends

Laser Ablation Devices Expected to Witness Considerable Growth Over the Forecast Period

Laser ablation treatment does not involve lengthy hospital stays or discomfort during the recovery process, which provides significant benefits to the patients who are treated for varicose veins. With the help of novel technologies and advancements in research activities by the key players in the studied market, there has been increased adoption of lasers in the treatment of varicose veins.

Laser ablation technology enables doctors to close smaller varicose veins and spider veins. This treatment involves emitting strong bursts of light onto the vein, making the affected veins disappear or fade. The use of laser treatment is increasing in developed nations due to the increasing healthcare expenditure and the growing inclination toward non-invasive procedures. According to a research study titled " Compression following treatment of superficial venous incompetence: systematic review" published in the British Journal of Surgery in May 2022, laser ablation therapy was cost-effective and the preferred initial treatment for symptomatic varicose veins having a diameter of at least 3 mm, with evidence of saphenous vein reflux. Also, there is intense competition among the local manufacturers of varicose vein lasers. With the upcoming advancements in lasers and the ease of treatment provided by the same, it is expected that the segment will grow in the future.

Moreover, increasing product launch by the key market players anticipated to boost the segment growth over the forecast period. For Instance, in April 2022, Ra Medical Systems, Inc., a medical device company focusing on developing its excimer laser system to treat vascular diseases, reported the United States Patent and Trademark Office has granted the company a patent for liquid-filled laser ablation with expanded distal optical windows.

Thus, owing to the aforementioned factors, the laser ablation devices market is expected to register healthy growth over the forecast period.

North America Expected to Dominate the Market Over the Forecast Period

North America holds the largest share of the market studied, and this trend is expected to continue over the forecast period. The major factors contributing to the growth of the varicose veins treatment market in North America include the well-developed healthcare systems in countries such as the United States and the presence of major players, which allows the higher availability of products in the market. Furthermore, due to the favorable reimbursement scenario, the people in the United States can access this treatment at an affordable cost.

According to the study titled "Risk assessment for varicose veins among city Police-A cross-sectional study" published in the Clinical Epidemiology and Global Health in December 2021, Varicose veins affect roughly 23% of adults in the United States. When spider telangiectasias and reticular veins are taken into account, the prevalence rises to 80% in men and 85% in women. The United States of America was found to be 1 in 22. Thus, the increasing burden of varicose veins in the American population is expected to drive the studied market in the North American region over the forecast period.

However, various strategies adopted by the key market players for market expansion such as product launch, merger and acquisition, collaboration and among other anticipated to boost the market in the region. For instance in April 2021, Medtronic has started an Investigation Device Exemption (IDE) study to see if the Abre venous self-expanding stent system, which is used to treat deep venous diseases, is effective and safe. Additionally, in Otober 2021, Venclose Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease recieved FDA 510(k) clearance for Venclose Maven, a novel radiofrequency ablation (RFA) catheter for minimally invasive treatment of incompetent perforator veins (IPVs).

Thus, owing to the aforementioned factors, the vericose vein treatment market is expected to register healthy growth over the forecast period.

Varicose Veins Treatment Market Competitor Analysis

The market for varicose vein treatment is moderately competitive and comprises mostly local players. A few international companies are present, but the local companies in different geographies majorly control the overall market. With the growing medical devices market, it is predicted that more companies will penetrate the market studied and hold substantial shares over the forecast period. The major players of the market include Medtronic plc, AngioDynamics Inc., Teleflex incorporated, Lumenis, Quanta System, Biolitec AG, Syneron Medical Ltd, and Vascular Solutions Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definitions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Preference for Minimally-invasive Surgeries
    • 4.2.2 Technological Advancements in Devices
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Procedure
    • 4.3.2 Risk Associated with the Vein Surgeries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Treatment Type
    • 5.1.1 Endovenous Ablation
    • 5.1.2 Injection Sclerotherapy
    • 5.1.3 Surgical Ligation/Stripping
  • 5.2 By Product
    • 5.2.1 Ablation Devices
      • 5.2.1.1 Radiofrequency Ablation Devices
      • 5.2.1.2 Laser Ablation Devices
    • 5.2.2 Venous Closure Products
    • 5.2.3 Surgical Products
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Candela Medical (Syneron Medical Ltd)
    • 6.1.2 Medtronic PLC
    • 6.1.3 Boston Scientific (Lumenis Corporation)
    • 6.1.4 El. En SpA Group (Quanta System)
    • 6.1.5 Teleflex Incorporated
    • 6.1.6 Eufoton SRL
    • 6.1.7 Biolitec AG (BioMed Technology Holdings Ltd)
    • 6.1.8 AngioDynamics Inc.
    • 6.1.9 Alma Lasers Ltd
    • 6.1.10 Sciton Inc.
    • 6.1.11 Won Tech Co. Ltd
    • 6.1.12 Dornier MedTech GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS